KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) FCF Margin (2016 - 2025)

Historic FCF Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to 49.02%.

  • Bristol Myers Squibb's FCF Margin rose 47300.0% to 49.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 31.86%, marking a year-over-year increase of 27600.0%. This contributed to the annual value of 28.87% for FY2024, which is 7600.0% up from last year.
  • Latest data reveals that Bristol Myers Squibb reported FCF Margin of 49.02% as of Q3 2025, which was up 47300.0% from 28.98% recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year FCF Margin high stood at 49.02% for Q3 2025, and its period low was 14.5% during Q2 2023.
  • For the 5-year period, Bristol Myers Squibb's FCF Margin averaged around 29.3%, with its median value being 30.55% (2022).
  • Over the last 5 years, Bristol Myers Squibb's FCF Margin had its largest YoY gain of 229200bps in 2021, and its largest YoY loss of -187100bps in 2021.
  • Bristol Myers Squibb's FCF Margin (Quarter) stood at 31.18% in 2021, then fell by -17bps to 25.95% in 2022, then surged by 32bps to 34.17% in 2023, then decreased by -4bps to 32.9% in 2024, then surged by 49bps to 49.02% in 2025.
  • Its FCF Margin stands at 49.02% for Q3 2025, versus 28.98% for Q2 2025 and 15.12% for Q1 2025.